登录 查看组织和合同定价。
选择尺寸
关于此项目
Conjugate:
unconjugated
Clone:
polyclonal
Application:
immunofluorescence
immunohistochemistry
immunohistochemistry
Species reactivity:
human
Citations:
7
Technique(s):
immunofluorescence: 0.25-2 μg/mL
immunohistochemistry: 1:50-1:200
immunohistochemistry: 1:50-1:200
Uniprot accession no.:
产品名称
Anti-RAB11FIP1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution, Ab1
biological source
rabbit
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
product line
Prestige Antibodies® Powered by Atlas Antibodies
form
buffered aqueous glycerol solution
species reactivity
human
enhanced validation
orthogonal RNAseq
Learn more about Antibody Enhanced Validation
technique(s)
immunofluorescence: 0.25-2 μg/mL
immunohistochemistry: 1:50-1:200
immunogen sequence
TGSAKHRLHPVKPMNAMATKVANCSLGTATIISENLNNEVMMKKYSPSDPAFAYAQLTHDELIQLVLKQKETISKKEFQVR
UniProt accession no.
shipped in
wet ice
storage temp.
−20°C
target post-translational modification
unmodified
Quality Level
Gene Information
human ... RAB11FIP1(80223)
Other Notes
Corresponding Antigen APREST76310
Physical form
Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide
Legal Information
Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany
General description
Rab11-family interacting protein 1 (Rab11-FIP1) is encoded by a gene mapped to human chromosome 8p11. The encoded protein is characterized with an amphipathic a-helix at carboxyl-terminal end involved in binding Rab11a. Rab11-FIP1 and Rab11a, along with other proteins, localize on plasma membrane recycling system vesicles in both non-polarized HeLa cells and polarized madin-darby canine kidney cells (MDCK).
Immunogen
Rab11 family-interacting protein 1 recombinant protein epitope signature tag (PrEST)
Application
All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.
The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies® protocols and other useful information.
The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies® protocols and other useful information.
Biochem/physiol Actions
Rab11-family interacting protein 1 (Rab11-FIP1) along with Rab11a regulates plasma membrane recycling. Human breast cancer cell lines show elevated expression of Rab11-FIP1 gene. Rab11-FIP1 controls adiponectin trafficking and release from the adipocyte.Rab11-FIP1 expression increases with increasing body mass index (BMI) of humans. Cell-based assay states that Rab11-FIP1A as a potential oncogene plays a role in cell cycle and apoptosis.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Features and Benefits
Prestige Antibodies® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.
Every Prestige Antibody is tested in the following ways:
Every Prestige Antibody is tested in the following ways:
- IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
- Protein array of 364 human recombinant protein fragments.
未找到合适的产品?
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Identification and characterization of a family of Rab11-interacting proteins.
Hales CM
The Journal of Biological Chemistry, 276(42), 39067-39075 (2001)
Cell-based assays suggest role for RAB11FIP1 in cell cycle and apoptosis
Leong WY
Cellular and Molecular Biology, 68(9), 12-16 (2008)
The Rab11-FIP1/RCP gene codes for multiple protein transcripts related to the plasma membrane recycling system.
Jin m and Goldenring JR
Biochimica et Biophysica Acta, 1759(6), 281-295 (2006)
The rab11 effector protein FIP1 regulates adiponectin trafficking and secretion.
Carson BP
PLoS ONE, 8(9) (2013)
Sung Pil Hong et al.
Nature communications, 10(1), 3840-3840 (2019-09-04)
Resistant tumours are thought to arise from the action of Darwinian selection on genetically heterogenous cancer cell populations. However, simple clonal selection is inadequate to describe the late relapses often characterising luminal breast cancers treated with endocrine therapy (ET), suggesting
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持